1-20 of 490
chronic lymphocytic leukemia refractory
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch
Journal: Blood
Blood (2021) 138 (2): 106–107.
https://doi.org/10.1182/blood.2021011937
Published: 2021
Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Carsten U. Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Kazem Nasserinejad, Arnon P. Kater
Journal: Blood
Blood (2021) 137 (8): 1117–1120.
https://doi.org/10.1182/blood.2020008608
Published: 2021
Includes: Supplemental data
Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson
Journal: Blood
Blood (2020) 136 (1): 4–6.
https://doi.org/10.1182/blood.2020005877
Published: 2020
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Sariya Wongsaengsak, MD, Myet Mon Zin, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 798.
https://doi.org/10.1182/blood-2019-123177
Published: 2019
Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Anthony R. Mato, MDMSCE, Stephen J Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Han W. Tun, MD, Muhamad Alhaj Moustafa, MD, Kaitlin Kennard, RN, BSN, Cara M King, MPH, Amber Koehler, PA-C, MS, Casey Aitken, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Barry Douglas Anderson, MD PhD, Allison C. Rosenthal, DO, Lindsey E. Roeker, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 810.
https://doi.org/10.1182/blood-2019-126192
Published: 2019
Journal Articles

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Chingiz Underbayev, MD PhD, Inhye E Ahn, MD, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, MD PhD, Liqiang Xi, MD, Mark Raffeld, MD, Sarah E. M. Herman, Adrian Wiestner, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1287.
https://doi.org/10.1182/blood-2019-127364
Published: 2019
Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3045.
https://doi.org/10.1182/blood-2019-124538
Published: 2019
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3047.
https://doi.org/10.1182/blood-2019-131025
Published: 2019
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Nicholas D'Cunha, MD, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Upama Sharma, Nimesh Adhikari, MD, Ye Aung, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5479.
https://doi.org/10.1182/blood-2019-123172
Published: 2019
Journal Articles

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Anita Sultan, MD, Bradley J. Grant, JD, Donald P. Quick, MD, Chandler Graf, Sriman Swarup, MDMBBS, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Somedeb Ball, MD, Ei Moe Phyu, MD, Myat Min Han, MD, Yin Mon Myat, MD, Nicholas D'Cunha, MD, Myint Aung Win, MDMBBS, Kyaw Zin Thein, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5480.
https://doi.org/10.1182/blood-2019-123231
Published: 2019
Journal Articles

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John McKay, DO, Taha Al-Juhaishi, MD, Lai Guanhua, MD PhD, Maciej Kmieciak, PhD, Roy Sabo, PhD, Ariel Sindel, DO, Victor Yazbeck, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5482.
https://doi.org/10.1182/blood-2019-126335
Published: 2019
Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5484.
https://doi.org/10.1182/blood-2019-129260
Published: 2019
Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5477.
https://doi.org/10.1182/blood-2019-130784
Published: 2019
Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5489.
https://doi.org/10.1182/blood-2019-123179
Published: 2019
Journal Articles

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Marcin M Machnicki, MSc, Patryk Górniak, Monika Pepek, MSc, Agnieszka Szymczyk, Elżbieta Iskierka-Jażdżewska, Pawel Steckiewicz, Aleksandra Bluszcz, Malgorzata Rydzanicz, PhD, Marek Hus, Rafal Ploski, MD PhD, Przemyslaw Juszczynski, Prof., MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Jamroziak, MD PhD, Bartosz Pula
Journal: Blood
Blood (2019) 134 (Supplement_1): 5456.
https://doi.org/10.1182/blood-2019-124693
Published: 2019
Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, MD PhD, Julie Dubois, Sabina Kersting, MD PhD, Lisbeth Enggaard, MD, Gerrit J Veldhuis, Rogier Mous, MD PhD, Clemens Mellink, PhD, Johan A Dobber, Christian Bjørn Poulsen, MD, Henrik Frederiksen, MD Prof, Ann Janssens, Ida Schjødt, MD PhD, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, MD, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, MD PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4292.
https://doi.org/10.1182/blood-2019-124377
Published: 2019
Journal Articles

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Adam S. Kittai, MD, Scott R Best, BS, Bria Thurlow, BSc, Basak Gokcora, Andrzej Stadnik, MPH, BS, Renee MacKinnon, Taylor Hashiguchi Rowland, BS, Daniel O. Persky, MD, Byung Park, PhD, Stephen E Spurgeon, MD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4295.
https://doi.org/10.1182/blood-2019-123586
Published: 2019
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4297.
https://doi.org/10.1182/blood-2019-130912
Published: 2019